Ernexa Therapeutics Inc (NASDAQ: ERNA) has seen a decline in its stock price by -13.17 in relation to its previous close of 0.19. However, the company has experienced a -8.73% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-10 that CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the “Common Stock”), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company’s Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.”
Is It Worth Investing in Ernexa Therapeutics Inc (NASDAQ: ERNA) Right Now?
Moreover, the 36-month beta value for ERNA is 5.57. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ERNA is 20.84M and currently, short sellers hold a 0.61% of that float. On June 10, 2025, ERNA’s average trading volume was 293.94K shares.
ERNA’s Market Performance
ERNA stock saw a decrease of -8.73% in the past week, with a monthly decline of -17.79% and a quarterly a decrease of -38.79%. The volatility ratio for the week is 2.58%, and the volatility levels for the last 30 days are 6.33% for Ernexa Therapeutics Inc (ERNA). The simple moving average for the last 20 days is -23.50% for ERNA stock, with a simple moving average of -71.87% for the last 200 days.
ERNA Trading at -19.17% from the 50-Day Moving Average
After a stumble in the market that brought ERNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.75% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ERNA starting from Cherington Charles, who purchase 3,768,397 shares at the price of $0.10 back on Apr 02 ’25. After this action, Cherington Charles now owns 20,401,602 shares of Ernexa Therapeutics Inc, valued at $394,174 using the latest closing price.
Stock Fundamentals for ERNA
Current profitability levels for the company are sitting at:
- -23.58 for the present operating margin
- 0.81 for the gross margin
The net margin for Ernexa Therapeutics Inc stands at -86.16. The total capital return value is set at 2.35. Equity return is now at value -2264.31, with -168.48 for asset returns.
Based on Ernexa Therapeutics Inc (ERNA), the company’s capital structure generated -0.94 points at debt to capital in total, while cash flow to debt ratio is standing at -4.91. The debt to equity ratio resting at -0.48. The interest coverage ratio of the stock is -2.11.
Currently, EBITDA for the company is -36.12 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 20.86. The receivables turnover for the company is 3.43for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.21.
Conclusion
To wrap up, the performance of Ernexa Therapeutics Inc (ERNA) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
